- Home
- TMDX
as of 12-05-2025 3:45pm EST
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ANDOVER |
| Market Cap: | 3.9B | IPO Year: | 2019 |
| Target Price: | $133.00 | AVG Volume (30 days): | 835.5K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.54 | EPS Growth: | 170.70 |
| 52 Week Low/High: | $55.00 - $156.00 | Next Earning Date: | 10-29-2025 |
| Revenue: | $566,354,000 | Revenue Growth: | 41.20% |
| Revenue Growth (this year): | 38.84% | Revenue Growth (next year): | 20.43% |
AI-Powered TMDX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of TransMedics Group Inc. (TMDX)
Chief Financial Officer
Avg Cost/Share
$139.62
Shares
920
Total Value
$128,450.40
Owned After
15,064
SEC Form 4
Director
Avg Cost/Share
$138.64
Shares
5,000
Total Value
$693,200.00
Owned After
12,134
SEC Form 4
See remarks
Avg Cost/Share
$145.22
Shares
3,000
Total Value
$435,660.00
Owned After
13,955
SEC Form 4
President & CEO
Avg Cost/Share
$114.00
Shares
8,775
Total Value
$1,000,350.00
Owned After
495,009
SEC Form 4
Director
Avg Cost/Share
$130.45
Shares
4,142
Total Value
$540,323.90
Owned After
2,866
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hernandez Gerardo | TMDX | Chief Financial Officer | Dec 4, 2025 | Sell | $139.62 | 920 | $128,450.40 | 15,064 | |
| Weill David | TMDX | Director | Dec 3, 2025 | Sell | $138.64 | 5,000 | $693,200.00 | 12,134 | |
| Ranganath Anil P. | TMDX | See remarks | Nov 25, 2025 | Sell | $145.22 | 3,000 | $435,660.00 | 13,955 | |
| Hassanein Waleed H | TMDX | President & CEO | Nov 17, 2025 | Buy | $114.00 | 8,775 | $1,000,350.00 | 495,009 | |
| Basile Edward M | TMDX | Director | Oct 29, 2025 | Sell | $130.45 | 4,142 | $540,323.90 | 2,866 |
Compare TMDX vs Leading Stocks
See how TMDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TMDX TransMedics Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.